InvestorSoup.com Issues Technical Trading Outlook for Opexa Therapeutics Inc.

• Press Release
• Source: InvestorSoup
• On 6:50 am EDT, Monday September 14, 2009

DALLAS, Sept. 14, 2009 (GLOBE NEWSWIRE) -- InvestorSoup.com announces an investment report featuring Opexa Therapeutics Inc. (Nasdaq:OPXA - News). The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

Related Quotes

Symbol	Price	Change
AIMM.OB	0.41	-0.04

{"s" : "aimm.ob,biib,ljpc,nvs,opxa","k" : "c10,l10,p20,t10","o" : "","j" : ""}

The investment report for Opexa Therapeutics Inc. (Nasdaq:OPXA - News) should be of particular interest to other biotechnology companies: Novartis AG (NYSE:NVS - News), Biogen Idec Inc. (Nasdaq:BIIB - News), AutoImmune Inc. (OTCBB:AIMM - News) and La Jolla Pharmaceutical Company (Nasdaq:LJPC - News).

It is available at: http://www.investorsoup.com/lp/OPXA

Get our alerts BEFORE the rest of the market. Follow us on Twitter: www.twitter.com/investorsoup

Opexa Therapeutics Inc. (Nasdaq:OPXA - News) is a biotechnology company that develops patient-specific cellular therapies to treat autoimmune diseases such as multiple sclerosis (MS) and diabetes. The Company's lead product candidate is Tovaxin(R), a novel T-cell vaccine for the treatment of MS specifically tailored to each patient's disease profile. The Company also has adult stem-cell technology in the preclinical development stage.

In the report, the analyst notes:

"On September 8, 2009, OPXA announced that analysis of data from its phase IIb study of Tovaxin showed that more than 83% of patients taking the drug for MS remained relapse free after a year. The announcement caused the Company's share price to more than triple to $5.66. OPXA also reported that the annualized relapse rate among MS patients taking its Tovaxin drug was 20%, 42% lower than relapse rates among patients taking a placebo. The next step in the development of Tovaxin is a phase III study, which is likely to be initiated in early 2010.

"On August 7, 2009, Novartis AG (NYSE:NVS - News) acquired OPXA's stem-cell technology, which was in early preclinical development. The Company received an initial payment of $3 million and will receive an additional $1 million technology transfer fee that is to be paid over the course of a six-month period. The initial payment, technology transfer fee, and development and commercial milestone payments could exceed $50 million not including royalties. OPXA will be able to receive royalty payments from the sale of any products resulting from the use of the technology and retains an option on certain manufacturing rights."

To read the entire report visit: http://www.investorsoup.com/lp/OPXA

See what investors say about these stocks at: http://www.stockhideout.com/

InvestorSoup.com is a small-cap research and investment commentary provider. InvestorSoup.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on InvestorSoup.com, please visit http://www.InvestorSoup.com.

InvestorSoup.com Disclosure

InvestorSoup.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. InvestorSoup.com is a web site wholly owned by BlueWave Advisors, LLC. Please read our report and visit our web site, InvestorSoup.com, for complete risks and disclosures.

InvestorSoup.com
Jeffrey Brown, Editor
(469)-252-3505
info@investorsoup.com